Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUREKA: Phase 2 Study to Optimize Neoadjuvant Therapy in HER2+ Early Breast Cancer
NCT07402473Phase 2Recruiting
- Sponsor
- Rutgers University
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab, pertuzumab in HER2-positive breast cancer, sponsored by Rutgers University. Started Mar 2026; status: recruiting.
02
Drugs
trastuzumabpertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT07402473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07402473.